



Alternative Model-Based Translational Drug Development

Guest Editors:

Dr. Francislaire Aparecida Dos Reis Lívero

Laboratory of Cardiometabolic Pharmacology, Department of Pharmacology, Federal University of Parana, Curitiba 81530-900, PR, Brazil

Dr. Arquimedes Gasparotto Junior

Laboratory of Cardiovascular Pharmacology (LaFaC), Federal University of Grande Dourados (UFGD), Rodovia Dourados-Itahum, km 12, P.O. Box 533, Dourados 79.804-970, MS, Brazil

Deadline for manuscript submissions:

31 December 2024

Message from the Guest Editors

Dear Colleagues,

This Special Issue aims to shed light on the latest advancements in alternative drug delivery models and their potential implications for translational medicine. Research areas may include, but are not limited to:

- Recent developments in nanotechnology-based drug delivery systems, including nanoparticles, liposomes, and micelles.
- Alternative models for drug delivery research, such as organoids, microfluidic systems, and computational modeling.
- Bioengineering strategies for personalized medicine, such as 3D printing of drug delivery devices and organs-on-chips.
- Development of patient-specific drug delivery systems, considering factors like genetic variations and disease-specific characteristics.
- Design and evaluation of preclinical models that better mimic human physiology and predict clinical outcomes.
- Development of novel targeting agents and strategies to improve drug accumulation at specific disease sites.
- Case studies on the clinical application of targeted drug delivery systems, highlighting their efficacy and potential impact on patient outcomes.
- Application of alternative models in studying drug transport, absorption, and distribution.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma